Pasi A Jänne, MD, Director, Lowe Center for Thoracic Oncology, Belfer Center for Applied Cancer Science, Senior Physician, Professor of Medicine at Harvard Medical School explains how he would treat 2nd line patients who received Keytruda or another PD-L1 targeting agent as part of 1st line therapy.
Treating Patients in 2nd Ling Setting after 1st Line Keytruda
